View : 350 Download: 0

The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)

Title
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)
Authors
Jo, Jae-CheolLee, Ho SupKim, KihyunLee, Je-JungYoon, Sung-SooBang, Soo-MeeKim, Jin SeokEom, Hyeon-SeokYoon, Dok HyunLee, YoojinShin, Ho-JinPark, YongLee, Won SikDo, Young RokMun, Yeung-ChulLee, Mark HongKim, Hyo JungKim, Sung-HyunKim, Min KyoungLim, Sung-NamCho, Su-HeePark, Seong KyuYi, Jun HoLee, Jae HoonKim, JinmiMin, Chang-KiKorean Multiple Myeloma Working
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2020
Journal Title
ANNALS OF HEMATOLOGY
ISSN
0939-5555JCR Link

1432-0584JCR Link
Citation
ANNALS OF HEMATOLOGY vol. 99, no. 2, pp. 309 - 319
Keywords
Multiple myelomaLenalidomide plus dexamethasoneEffectivenessSurvivalReal-world evidence
Publisher
SPRINGER
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Although lenalidomide plus dexamethasone (RD) is a therapeutic option for relapsed/refractory multiple myeloma (RRMM), limited real-world clinical data exist. The purpose of this study was to estimate efficacy and safety of RD in RRMM patients of the clinical practice. Data from patients at 25 university hospitals in South Korea between October 2009 and December 2016 were collected retrospectively. We report the effectiveness and safety of RD in 546 RRMM patients in routine clinical practice in South Korea. Patients (median age, 65 years) typically received median 7 cycles of RD, and 184 (33.7%) patients were treated with 10 or more cycles of RD. Patients with renal impairment (CLCr < 40 mL/min; 10.4%), comorbid conditions (>= 2; 12.0%), and poor performance status (>= 2; 25.1%) were included. The overall response rate was 64.2%: complete response (13.1%), very good partial response (VGPR 19.9%). With median follow-up duration of 18.6 months, median PFS and OS were 11.2 months and 25.2 months, respectively. In multivariate analysis, less than 2 comorbid conditions, normal LDH, failed one chemotherapy prior to RD, and >= 10 cycles of RD therapy had significantly prolonged PFS (P = 0.007, P = 0.011, P = 0.007, and P < 0.001, respectively). Adverse events were acceptable. RD is effective and safe in real-life clinical practice, including patients with comorbidities. RD is an effective and safe treatment in a real clinical setting which includes patients with comorbidities. Early and continual use of RD treatment may improve RRMM survival outcomes.
Show the fulltext
DOI
10.1007/s00277-019-03904-7
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE